Merz Aesthetics announced that Xeomin (incobotulinumtoxinA) has been approved for the temporary improvement in the appearance of moderate to severe glabellar lines, or frown lines between the eyebrows, in adult patients. The approval of Xeomin is based on the results of two clinical trials involving 16 investigational sites and included 547 healthy adult patients. In both studies, Xeomin significantly improved the appearance of glabellar lines 30 days following the first injection, when compared to placebo.
Xeomin is expected to be available for aesthetic use in the spring of 2012. Xeomin is already indicated and available from Merz Pharmaceuticals for the treatment of cervical dystonia in adults, to reduce severity of abnormal head position and neck pain in both botulinum toxin-naïve and previously treated patients and for blepharospasm in adults previously treated with onabotulinumtoxinA.
For more information visit www.merzaesthetics.com/en-US.